138 related articles for article (PubMed ID: 12189139)
1. Alanine-scanning mutagenesis of alpha-helix D segment of interleukin-13 reveals new functionally important residues of the cytokine.
Madhankumar AB; Mintz A; Debinski W
J Biol Chem; 2002 Nov; 277(45):43194-205. PubMed ID: 12189139
[TBL] [Abstract][Full Text] [Related]
2. Interleukin 13 mutants of enhanced avidity toward the glioma-associated receptor, IL13Ralpha2.
Madhankumar AB; Mintz A; Debinski W
Neoplasia; 2004; 6(1):15-22. PubMed ID: 15068667
[TBL] [Abstract][Full Text] [Related]
3. Mutants of interleukin 13 with altered reactivity toward interleukin 13 receptors.
Thompson JP; Debinski W
J Biol Chem; 1999 Oct; 274(42):29944-50. PubMed ID: 10514477
[TBL] [Abstract][Full Text] [Related]
4. Molecular targeting of malignant gliomas with novel multiply-mutated interleukin 13-based cytotoxins.
Nash KT; Thompson JP; Debinski W
Crit Rev Oncol Hematol; 2001; 39(1-2):87-98. PubMed ID: 11418305
[TBL] [Abstract][Full Text] [Related]
5. Expression of interleukin 13 receptor in glioma and renal cell carcinoma: IL13Ralpha2 as a decoy receptor for IL13.
Bernard J; Treton D; Vermot-Desroches C; Boden C; Horellou P; Angevin E; Galanaud P; Wijdenes J; Richard Y
Lab Invest; 2001 Sep; 81(9):1223-31. PubMed ID: 11555670
[TBL] [Abstract][Full Text] [Related]
6. T cells redirected to interleukin-13Rα2 with interleukin-13 mutein--chimeric antigen receptors have anti-glioma activity but also recognize interleukin-13Rα1.
Krebs S; Chow KK; Yi Z; Rodriguez-Cruz T; Hegde M; Gerken C; Ahmed N; Gottschalk S
Cytotherapy; 2014 Aug; 16(8):1121-31. PubMed ID: 24841514
[TBL] [Abstract][Full Text] [Related]
7. Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells.
Kahlon KS; Brown C; Cooper LJ; Raubitschek A; Forman SJ; Jensen MC
Cancer Res; 2004 Dec; 64(24):9160-6. PubMed ID: 15604287
[TBL] [Abstract][Full Text] [Related]
8. A novel ligand delivery system to non-invasively visualize and therapeutically exploit the IL13Rα2 tumor-restricted biomarker.
Nguyen V; Conyers JM; Zhu D; Gibo DM; Hantgan RR; Larson SM; Debinski W; Mintz A
Neuro Oncol; 2012 Oct; 14(10):1239-53. PubMed ID: 22952195
[TBL] [Abstract][Full Text] [Related]
9. Molecular expression analysis of restrictive receptor for interleukin 13, a brain tumor-associated cancer/testis antigen.
Debinski W; Gibo DM
Mol Med; 2000 May; 6(5):440-9. PubMed ID: 10952023
[TBL] [Abstract][Full Text] [Related]
10. Characterization of a recombinant herpes simplex virus 1 designed to enter cells via the IL13Ralpha2 receptor of malignant glioma cells.
Zhou G; Roizman B
J Virol; 2005 May; 79(9):5272-7. PubMed ID: 15827141
[TBL] [Abstract][Full Text] [Related]
11. Expression of a restrictive receptor for interleukin 13 is associated with glial transformation.
Debinski W; Slagle B; Gibo DM; Powers SK; Gillespie GY
J Neurooncol; 2000 Jun; 48(2):103-11. PubMed ID: 11083073
[TBL] [Abstract][Full Text] [Related]
12. Structure-function analysis of the C-terminal segment of human interleukin-6.
Li X; Rock F; Chong P; Cockle S; Keating A; Ziltener H; Klein M
J Biol Chem; 1993 Oct; 268(30):22377-84. PubMed ID: 7693665
[TBL] [Abstract][Full Text] [Related]
13. Engineered IL13 variants direct specificity of IL13Rα2-targeted CAR T cell therapy.
Stern LA; Gholamin S; Moraga I; Yang X; Saravanakumar S; Cohen JR; Starr R; Aguilar B; Salvary V; Hibbard JC; Kalbasi A; Shepphird JK; O'Hearn J; Garcia KC; Brown CE
Proc Natl Acad Sci U S A; 2022 Aug; 119(33):e2112006119. PubMed ID: 35939683
[TBL] [Abstract][Full Text] [Related]
14. Novel anti-brain tumor cytotoxins specific for cancer cells.
Debinski W; Gibo DM; Obiri NI; Kealiher A; Puri RK
Nat Biotechnol; 1998 May; 16(5):449-53. PubMed ID: 9592393
[TBL] [Abstract][Full Text] [Related]
15. Characterization of lactogen receptor-binding site 1 of human prolactin.
Kinet S; Goffin V; Mainfroid V; Martial JA
J Biol Chem; 1996 Jun; 271(24):14353-60. PubMed ID: 8662911
[TBL] [Abstract][Full Text] [Related]
16. Characterization of the interaction between interleukin-13 and interleukin-13 receptors.
Arima K; Sato K; Tanaka G; Kanaji S; Terada T; Honjo E; Kuroki R; Matsuo Y; Izuhara K
J Biol Chem; 2005 Jul; 280(26):24915-22. PubMed ID: 15870068
[TBL] [Abstract][Full Text] [Related]
17. Structural model of human IL-13 defines the spatial interactions with the IL-13Ralpha/IL-4Ralpha receptor.
Zuegg J; Webb DC; Foster PS; Casarotto MG
Immunol Cell Biol; 2001 Aug; 79(4):332-9. PubMed ID: 11488979
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-13 is a potent activator of JAK3 and STAT6 in cells expressing interleukin-2 receptor-gamma and interleukin-4 receptor-alpha.
Malabarba MG; Rui H; Deutsch HH; Chung J; Kalthoff FS; Farrar WL; Kirken RA
Biochem J; 1996 Nov; 319 ( Pt 3)(Pt 3):865-72. PubMed ID: 8920992
[TBL] [Abstract][Full Text] [Related]
19. Solution structure of human IL-13 and implication for receptor binding.
Moy FJ; Diblasio E; Wilhelm J; Powers R
J Mol Biol; 2001 Jun; 310(1):219-30. PubMed ID: 11419948
[TBL] [Abstract][Full Text] [Related]
20. A comprehensive alanine scanning mutagenesis of the Escherichia coli transcriptional activator SoxS: identifying amino acids important for DNA binding and transcription activation.
Griffith KL; Wolf RE
J Mol Biol; 2002 Sep; 322(2):237-57. PubMed ID: 12217688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
